You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Truxima®

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Hodgkin's Lymphoma Trial in Vitoria-Gasteiz (RiTUXimab Injection [Truxima])

Recruiting
  • Non-Hodgkin's Lymphoma
  • RiTUXimab Injection [Truxima]
  • Vitoria-Gasteiz, Alava, Spain
    Hospital Universitario Araba- Sede Txagorritxu
Mar 30, 2022

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Lymphoma Trial (BYON4228 + Rituximab)

Not yet recruiting
  • Lymphoma
  • BYON4228 + Rituximab
  • (no location specified)
Feb 20, 2023

Anemia, Sickle Cell Trial in New York (Siplizumab, Exchange Transfusion, Total Body Irradiation)

Recruiting
  • Anemia, Sickle Cell
  • New York, New York
    Columbia University Irving Medical Center
Oct 9, 2023

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS Trial in Amsterdam

Recruiting
  • Multiple Sclerosis
  • +5 more
  • Amsterdam, Netherlands
    Amsterdam UMC, location VUmc
Apr 17, 2023

Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)

Not yet recruiting
  • Splenic Marginal Zone Lymphoma
  • Aarhus, Denmark
  • +4 more
Feb 17, 2023

Rheumatoid Arthritis Trial in Belgium (Rituximab)

Not yet recruiting
  • Rheumatoid Arthritis
  • Merksem, Antwerpen, Belgium
  • +6 more
Aug 17, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
  • (no location specified)
Nov 30, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Primary CNS Lymphoma Trial in Seoul (Rituximab, lenalidomide)

Recruiting
  • Primary CNS Lymphoma
  • Rituximab, lenalidomide
  • Seoul, Korea, Republic of
    Samsung Medical Center
Feb 4, 2022

Lymphoma, Large B-Cell, Diffuse (DLBCL) Trial in Jerusalem, Seoul, Warszawa (Zilovertamab Vedotin, Cyclophosphamide,

Recruiting
  • Lymphoma, Large B-Cell, Diffuse (DLBCL)
  • Zilovertamab Vedotin
  • +6 more
  • Victoria, British Columbia, Canada
  • +19 more
Jan 19, 2023

Oncology Patients Receiving Chemo Trial in United States (Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as

Completed
Has Results
  • Oncology Patients Receiving Chemotherapy
  • Cetirizine HCl 10 mg/mL
  • +2 more
  • Napa, California
  • +6 more
Apr 25, 2022

ANCA Associated Vasculitis, Granulomatosis With Polyangiitis Trial in United Kingdom (Belimumab, Rituximab, Prednisolone)

Active, not recruiting
  • ANCA Associated Vasculitis
  • Granulomatosis With Polyangiitis
  • Cambridge, United Kingdom
  • +5 more
Feb 21, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in United States (FT596, Cyclophosphamide, Fludarabine)

Recruiting
  • Lymphoma, B-Cell
  • Chronic Lymphocytic Leukemia
  • Chicago, Illinois
  • +8 more
Jun 21, 2022

IgA Vasculitis Trial in France (Rituximab Injection, )

Recruiting
  • IgA Vasculitis
  • Rituximab Injection
  • placebo
  • Brest, France
  • +13 more
Apr 8, 2022

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +3 more
  • Clinical Observation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

Not yet recruiting
  • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
  • Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Biopsy
  • +5 more
  • New Brunswick, New Jersey
  • +2 more
Mar 23, 2023

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Lymphoma, Mantle-Cell Trial in Czechia (Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • Polatuzumab vedotin
  • +2 more
  • Brno, Czechia
  • +6 more
May 28, 2021

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
Mar 9, 2022